Paul W Burridge

Paul W Burridge, PhD is an Associate Professor in the Department of Pharmacology at Northwestern University's Feinberg School of Medicine and a founding faculty member of the Center for Pharmacogenomics. His laboratory specializes in human induced pluripotent stem cell (hiPSC) modeling for pharmacogenomics and cardio-oncology research.

Dr. Burridge's research focuses on understanding how genomic variation influences drug efficacy and toxicity, particularly in cancer therapy-induced cardiovascular complications. His lab pioneered several key methodologies including the first directed cardiac differentiation protocol, non-integrating blood-to-iPSC reprogramming, and chemically defined differentiation protocols. Current projects span cardio-oncology, arrhythmia mechanisms, regenerative medicine, hiPSC models of breast cancer, and cultivated meat applications.

Analysis of his 15 most recent publications reveals a strong emphasis on pharmacogenomics of anthracycline cardiotoxicity, with significant focus on genomic risk prediction in childhood cancer survivors, molecular mechanisms of cardiotoxicity, and development of cardioprotective strategies. His work increasingly integrates large-scale genomic analysis with hiPSC modeling to establish causal relationships between genetic variants and clinical outcomes.

• Fellow of American Heart Association (2016)
• Recipient of NCI R01 grant for Nilotinib Induced Artery Disease research
• NIH NHLBI Pathway to Independence Award recipient
• Editorial Board Member, Journal of Molecular and Cellular Cardiology (2020-present)
• Associate Editor, JACC CardioOncology (2018-present)

Dr. Burridge advises multiple postdoctoral fellows including Ning Ge (cardiac arrhythmia modeling), Praeploy Pongpamorn (chemically defined differentiation), Nnamdi Uche (population-specific doxorubicin susceptibility), and George Gibbons. His lab has secured substantial grant funding for projects including large-scale hiPSC production, cardiotoxicity screening platforms, and novel drug discovery initiatives. The Burridge lab maintains extensive resources including high-throughput screening systems, CRISPR editing platforms, and bioreactor-based differentiation systems, all developed with a focus on eliminating animal-derived products from research.